I recently did a stock screen to find the number of U.S. stocks trading over $200. Out of 5,910 stocks, just 19 fit the bill. Among the list of companies at the time were Berkshire Hathaway (NYSE:BRK-A), Google (Nasdaq:GOOG) and Priceline.com (Nasdaq:PCLN).

However, among some of America's elite is Atrion Corporation (Nasdaq:ATRI), a Texas-based micro cap that produces niche medical products. Atrion, along with Biglari Holdings (NYSE:BH), are the only micro-caps among the group of 19 stocks. Atrion will give any of these big companies a run for their money.

Investopedia Markets: Explore the best one-stop source for financial news, quotes and insights.

Always Makes Money

I went back as far as 1990 and on only one occasion, 1997, did Atrion generate an operating loss. Even then, it would have made $1.5 million on an operating basis if the $4.8 million impairment loss for some of its patents is excluded. This is where it gets tricky. Atrion used to be known as AlaTenn Resources Inc. and operated natural gas pipelines.

In 1994, it began acquiring medical products businesses. First, it acquired Atrion Medical Products in April 1994, then it bought Halkey-Roberts in May 1996, and finally, in January 1998, it purchased QMI Medical, the cardiovascular and intravenous fluid division of Quest Medical Inc.

At the same time, it sold all of its natural gas businesses for about $38.2 million in 1997. From 1998 onward, it's been strictly a medical products business, making money for 14 straight years. In that time, revenues have grown from $30.3 million at the end of 1997 to an estimated $119 million in 2011, or 10.3% compounded annually.

Not a huge grower, its niche position allows it to make good money. In 1997, as mentioned previously, it lost $2 million on continuing operations. In 2011, operating income will be around $38 million with earnings per share of $12.84.(To know more about income statements, read Understanding The Income Statement.)

Lots of Cash

Generating more than $20 million in free cash flow annually, Atrion currently has $19.45 in cash per share. The odds of it not being able to pay its annual dividend of $1.98 is slim to none. In the past five years, it's increased its quarterly dividend at least once per annum, averaging just under 20% for each increase.

In 2010, shareholders received the motherlode, as it paid not one, but two special dividends. In January 2010, it paid a $6 special dividend and then, in time for Christmas, it paid a second $3 special dividend. That's $9 in cash that went out the door and it barely blinked finishing 2010 with $41.7 million in cash and investments.

As of the third quarter ended Sept. 30, 2011, its level of cash and investments was up 27% from the end of 2010 to $52.7 million. Considering the two special dividends amounted to an expense of $18 million in cash, it could easily afford to do the same thing in 2012. I doubt it will, but it could.

The Business Itself

Atrion generates revenue from four product lines: Fluid Delivery, Cardiovascular, Ophthalmology and Other. The fluid delivery and cardiovascular products account for approximately two-thirds of its overall revenue.

The most consistent product line in terms of revenue growth is its fluid delivery valves, which have seen revenue increases in each of the last six fiscal years and 2011 appears be no different. It's not flashy about what it does and that's what's so attractive about it. Proponents of "Made in America" policies will like the fact its products are produced exclusively in Florida, Alabama and Texas, with no offshore production.

With the exception of Novartis (NYSE:NVS), which accounts for 14% of its sales, no other organization represents more than 10% of revenue. It's sufficiently diversified, both in terms of product and customer mix. Most importantly, Atrion's revenues outside of the U.S. and Canada represent almost a quarter of its overall business and are rising at a moderate pace. Overall, its business appears very sound.

The Bottom Line

Atrion seems to do everything well. In the third quarter, it repurchased 8,000 of its shares at an average price of $189.12 a share. As of January 18, its stock is up 27% since the buyback. Over the past decade it's up 21.1% annually compared to 3.5% for the S&P 500. Hold this stock for 20 years and you might just be looking at a future mid cap. Slow and steady wins the race. (For additional reading, check out 5 Must-Have Metrics For Value Investors.)

Use the Investopedia Stock Simulator to trade the stocks mentioned in this stock analysis, risk free!
At the time of writing, Will Ashworth did not own shares in any of the companies mentioned in this article.

Related Articles
  1. Stock Analysis

    Starbucks: Profiting One Cup at a Time (SBUX)

    Starbucks is everywhere. But is it a worthwhile business? Ask the shareholders who've made it one of the world's most successful companies.
  2. Stock Analysis

    How Medtronic Makes Money (MDT)

    Here's the story of an American medical device firm that covers almost every segment in medicine and recently moved to Ireland to pay less in taxes.
  3. Investing News

    Latest Labor Numbers: Good News for the Market?

    Some economic numbers are indicating that the labor market is outperforming the stock market. Should investors be bullish?
  4. Investing News

    Stocks with Big Dividend Yields: 'It's a Trap!'

    Should you seek high yielding-dividend stocks in the current investment environment?
  5. Investing News

    Should You Be Betting with Buffett Right Now?

    Following Warren Buffett's stock picks has historically been a good strategy. Is considering his biggest holdings in 2016 a good idea?
  6. Products and Investments

    Cash vs. Stocks: How to Decide Which is Best

    Is it better to keep your money in cash or is a down market a good time to buy stocks at a lower cost?
  7. Investing News

    Who Does Cheap Oil Benefit? See This Stock (DG)

    Cheap oil won't benefit most companies, but this retailer might buck that trend.
  8. Investing

    How to Ballast a Portfolio with Bonds

    If January and early February performance is any guide, there’s a new normal in financial markets today: Heightened volatility.
  9. Stock Analysis

    Performance Review: Emerging Markets Equities in 2015

    Find out why emerging markets struggled in 2015 and why a half-decade long trend of poor returns is proving optimistic growth investors wrong.
  10. Investing News

    The UAE: An Emerging Economy for Investors

    The learning from UAE on how it succeeded with timely diversification when the BRICS nations and the neighboring oil-rich economies faced challenges.
  1. How do dividends affect retained earnings?

    When a company issues a cash dividend to its shareholders, the retained earnings listed on the balance sheet are reduced ... Read Full Answer >>
  2. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  3. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  4. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>
  5. What types of capital are not considered share capital?

    The money a business uses to fund operations or growth is called capital, and there are a number of capital sources available. ... Read Full Answer >>
  6. What is the difference between issued share capital and subscribed share capital?

    The difference between subscribed share capital and issued share capital is the former relates to the amount of stock for ... Read Full Answer >>
Trading Center